Cytomegalovirus specific polyfunctional T-cell responses expressing CD107a predict control of CMV infection after liver transplantation
Por:
Carvalho-Gomes, A, Cubells, A, Pallares, C, Corpas-Burgos, F, Berenguer, M, Aguilera, V and Lopez-Labrador, F
Publicada:
1 ene 2022
Ahead of Print:
1 dic 2021
Categoría:
Immunology
Resumen:
Cytomegalovirus (CMV) viral load after liver transplantation (LT) is controlled by cell mediated immune responses (CMI). Quantification of CMV-specific T-cells may identify patients who control CMV spontaneously and avoid expensive and potentially toxic antiviral therapies. Prospective post-LT clinical, virological and immunological monitoring was carried out up to 1-year post-LT in a cohort of adult recipients. The CMV-specific T-cell response was characterized using flow cytometry intracellular cytokine staining in 49 LT recipients-R (79.6% R+, 20.4% R-). CMV infection occurred in 24 patients (18 D+/R+ and 6 D+/R-). Only patients with undetectable polyfunctional CMV-specific CD4+ T-cells developed CMV infection. Predictive models showed that polyfunctional CMV-specific CD4+ T-cells pre-existing before LT are protective for CMV reactivation posttransplantation. Quantitation of CD4+ T-cell responses to CMV may be a useful marker for spontaneous control of viral replication to tailor antiviral prophylaxis after LT.
Filiaciones:
Carvalho-Gomes, A:
Hosp U&P LaFe, Inst Invest Sanitaria La Fe, Hepatol HBP Surg & Transplant Unit, Liver Transplantat & Hepatol Lab, Valencia, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, CIBERehd, Madrid, Spain
Cubells, A:
Hosp U&P LaFe, Inst Invest Sanitaria La Fe, Hepatol HBP Surg & Transplant Unit, Liver Transplantat & Hepatol Lab, Valencia, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, CIBERehd, Madrid, Spain
Pallares, C:
Hosp U&P LaFe, Inst Invest Sanitaria La Fe, Hepatol HBP Surg & Transplant Unit, Liver Transplantat & Hepatol Lab, Valencia, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, CIBERehd, Madrid, Spain
:
Fdn Fomento Invest Sanitaria & Biomed Comunidad V, Av Catalunya 21, Valencia 46020, Spain
Inst Salud Carlos III, CIBERESP, Madrid, Spain
Berenguer, M:
Hosp U&P LaFe, Inst Invest Sanitaria La Fe, Hepatol HBP Surg & Transplant Unit, Liver Transplantat & Hepatol Lab, Valencia, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, CIBERehd, Madrid, Spain
Hosp Univ & Politecn La Fe, Liver Transplantat & Hepatol Unit, Valencia, Spain
Univ Valencia, Med Sch, Dept Med, Valencia, Spain
Aguilera, V:
Hosp U&P LaFe, Inst Invest Sanitaria La Fe, Hepatol HBP Surg & Transplant Unit, Liver Transplantat & Hepatol Lab, Valencia, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, CIBERehd, Madrid, Spain
Hosp Univ & Politecn La Fe, Liver Transplantat & Hepatol Unit, Valencia, Spain
:
Inst Salud Carlos III, CIBERESP, Madrid, Spain
Fdn Fomento Invest Sanitaria & Biomed Comunidad V, Ctr Super Salud Publ, Virol Lab, Genom & Hlth Area, Valencia, Spain
hybrid
|